Business Insider

Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block

Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use Lower extremity study defined safety and pharmacokinetic profile through 120 hours Timing for resubmission of ...
Seeking Alpha

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX),, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
Seeking Alpha

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
WDTN

Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures

TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Monthly Prescribing Reference

Exparel Application Under Review for Sciatic and Femoral Nerve Blocks

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...
Monthly Prescribing Reference

Exparel Gets Expanded Approval for Sciatic and Adductor Canal Nerve Blocks

In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...